Cellectis (Cellectis) Total Liabilities

: $133.58 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Cellectis's Total Liabilities for the quarter that ended in Sep. 2023 was $133.58 Mil.

Cellectis's quarterly Total Liabilities increased from Mar. 2023 ($130.92 Mil) to Jun. 2023 ($131.12 Mil) and increased from Jun. 2023 ($131.12 Mil) to Sep. 2023 ($133.58 Mil).

Cellectis's annual Total Liabilities declined from Dec. 2020 ($160.63 Mil) to Dec. 2021 ($145.60 Mil) and declined from Dec. 2021 ($145.60 Mil) to Dec. 2022 ($135.28 Mil).

Cellectis Total Liabilities Historical Data

The historical data trend for Cellectis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

50.57

112.00

160.63

145.60

135.28

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															133.97	135.28	130.92	131.12	133.58

Cellectis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cellectis's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	62.995	+	(62.927	+	9.353
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	135.28

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	261.216	-	125.941
	=	135.28

Cellectis's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.954	+	(70.813	+	18.81
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	133.58

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	209.7	-	76.123
	=	133.58

Cellectis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cellectis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.